Curis, Inc. (NASDAQ:CRIS) Files An 8-K Other Events
Item 8.01. Other Events
On December 6, 2019, Curis, Inc. (the Company) issued a press release announcing preliminary clinical data from its ongoing fimepinostat Phase 1 combination study with venetoclax in patients with relapsed or refractory diffuse large B-cell lymphoma. In addition, the Company issued a press release announcing preliminary clinical data from its ongoing CA-4948 dose escalating Phase 1 clinical study in patients with non-Hodgkin lymphomas.
The full text of the press releases issued in connection with these announcements are attached as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| 99.2 | | Press Release dated December 6, 2019. |
CURIS INC Exhibit
EX-99.1 2 d98029dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PRESS RELEASE Curis Announces Positive Safety,…
To view the full exhibit click here
About Curis, Inc. (NASDAQ:CRIS)
Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.
